Clinical Trial Update: HANDLE-a Real World Study on Satralizumab in NMOSD

View source ↗

Summary

A real-world study assessing satralizumab for neuromyelitis optica spectrum disorders is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Enspryng (satralizumab)

Snippet

Sponsor: Huashan Hospital | Conditions: Neuromyelitis Optica Spectrum Disorders (NMOSD) | Status: NOT_YET_RECRUITING